Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy.
Xuying Pei, Meng Lv, Xiaozheng Zhao et al.
✦ AI-curated · Sources linked
In 30 seconds
This comparative study evaluated InstanCAR-T, a rapid CD19 CAR-T manufacturing protocol enriched for CD45RA-negative T cells, against conventional CAR-T in laboratory assays, murine B-ALL models, and a Phase I clinical trial. The protocol reduced ex vivo culture to 3 days and showed improved in vitro viability, proliferation, and cytotoxicity, with greater expansion and persistence in vivo. In the clinical comparison, response rates were comparable, while the proportion achieving minimal residual disease-negative remission was numerically higher with InstanCAR-T; the abstract provides no numerical clinical effect estimate.
Key findings
- InstanCAR-T reduced ex vivo culture to 3 days while enriching CD45RA-negative T-cell subsets.
- Laboratory assays showed enhanced viability, proliferation, and cytotoxicity compared with conventional CAR-T.
- In murine B-ALL models, InstanCAR-T showed improved expansion and long-term persistence with durable tumor control.
- Clinical response rates were comparable, with a numerically higher proportion of minimal residual disease-negative remission for InstanCAR-T.
Why it matters
Rapid CAR-T manufacture may address the challenge of producing cells that retain durable activity. These findings suggest that enriching for CD45RA-negative T cells can support persistence and immune features associated with cellular fitness, while early clinical results indicate comparable response rates and a possible difference in MRD-negative remission. The clinical evidence remains preliminary.
What to keep in mind
The clinical evidence comes from a Phase I trial, and the abstract reports no numerical clinical effect estimates. The higher proportion of MRD-negative remission is described as numerical, not as a demonstrated statistically significant difference.